Form 4: Cara Therapeutics CEO Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Christopher Posner, CEO of Cara Therapeutics, sold 583 shares of common stock on February 28, 2025, to cover tax obligations related to vesting restricted stock units.
Summary
- On February 28, 2025, Christopher Posner, the President and CEO of Cara Therapeutics, sold 583 shares of the company's common stock.
- The sale was executed at a weighted average price of $4.75 per share, with individual transactions ranging from $4.75 to $4.99.
- This transaction was conducted under a pre-arranged 'sell to cover' arrangement adopted on November 2, 2022, to satisfy tax withholding obligations triggered by the vesting of restricted stock units.
- Following the transaction, Posner directly owns 13,109 shares of Cara Therapeutics common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The filing represents a routine transaction to cover tax obligations and doesn't suggest any significant change in the executive's view of the company.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This sale appears to be routine, related to tax obligations, and doesn't necessarily indicate a change in the executive's long-term outlook for the company.
Stakeholder Impact
- The sale of shares by the CEO could have a minor impact on shareholder sentiment, although it is likely to be viewed as a routine transaction.
Key Dates
| Date | Description |
|---|---|
| 2022-11-02 | Date the reporting person adopted a 'sell to cover' arrangement in accordance with Rule 10b5-1. |
| 2025-02-28 | Date of the stock sale transaction. |
| 2025-03-04 | Date of the report filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.